Brain natriuretic peptide correlates with troponin T in patients with renal failure

Acta Cardiologica

Volumn 62, Issue 2, 2007, Pages 171-176

  Sahinarslan, Asife ^a,c   Guz, Galip ^b   Okyay, Kaan ^a   Torer, Nihan ^b   Bali, Musa ^b   Sindel, Şükrü ^b   Cengel, Atiye ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b Department of Nephrology ^*  (Turkey)

^c BAYINDIR HOSPITAL   (Turkey)

Author keywords

Brain natriuretic peptide; Cardiac troponin T; Chronic renal failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TROPONIN T;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE SEPTUM; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL DIALYSIS; STROKE VOLUME; TROPONIN T;

EID: 34247482794     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.62.2.2020238     Document Type: Article

References (41)

1. Morbidity and mortality of renal dialysis: a NIH consensus conference statement Ann Intern Med 1994; 121: 62-70.
2. Byrne C, Vernon P, Cohen JJ. Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 1994; 231: 34-36.
3. Kjellstrand C, Hylander B, Collins AC. Mortality on dialysis - on the influence of early start, patient characteristics and transplantation and acceptance rates. Am J Kidney Dis 1990; 15: 483-90.
4. US Renal Data System: Causes of death. Am J Kidney Dis 1997; (Suppl 1) 30: S107-S117.
5. Brunner FP, Selwood NH. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney Int 1992; (suppl) 38: S4-S15.
6. Zoccali C. Cardiovascular risks in uremic patients: is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-6.
7. Li D, Keffer J, Conny K, Vazquez M, Jialal I. Nonspecific elevation of troponin T levels in patients with chronic renal failure. Clin Biochem 1995; 28: 474-7.
8. Haller C, Stevanovich A, Katus HA. Are cardiac troponins reliable, serodiagnostic markers of cardiac ischemia in end stage renal disease? Nephrol Dial Transplant 1996; 11: 941-4.
9. Ishii J, Ishikawa T, Yukitake J, Nagamura Y, Ito M, Wang JH, Kato Y, Hiramitsu S, Inoue S, Kondo T, Morimoto S, Nomura M, Watanabe Y, Hishida H. Clinical specificity of a second generation cardiac troponin T assay in patients with chronic renal failure. Clin Chim Acta 1998; 270: 183-8.
10. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Cardiac troponin T predicts the mortality in patients with end stage renal disease. Circulation 2000; 102: 1964-9.
11. Apple F, Sharkey S, Hoeft P. Prognostic value of serum cardiac troponin I and troponin T in chronic dialysis patients: A 1-year outcomes analysis. Am J Kidney Dis 1997; 29: 399-403.
12. Ooi D, Zimmeran D, Graham J, Wells GA. Cardiac troponin T predicts long term outcomes in hemodialysis patients. Clinical Chemistry 2001; 47: 412-7.
13. İshii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, Ishikawa T, Kurokawa H, Hirano T, Kondo T, Nagamura Y, Ezaki K, Hishida H. Risk stratification using serum concentrations of cardiac troponin T in patients with end stage renal disease on chronic maintenance dialysis. Clin Chim Acta 2001; 312: 69-79.
14. Porter G, Norton T, Bennett B. Troponin T, a predictor of death in chronic hemodialysis patients. Eur Heart J 1998; 19 (Suppl N): N 34-N37.
15. Khan A, Wattanasuwan N, Mehta N, Tun A, Singh N, Singh HK, Vasavada BC, Sacchi TJ. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis. J Am Coll Cardiol 2001; 38: 991-8.
16. Lang K, Shindler S, Forberger C. Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. Clinical Nephrology 2001; 56: 44-51.
17. de Filippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353-9.
18. Yu CM, Sanderson JE. Plasma brain natriuretic peptide - an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999; 1: 59-65.
19. Motwani JG, McAlphine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993; 341: 1109-13.
20. Maeda K, Tsutamato T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-32.
21. Richards AM, Doughtye R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG; Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781-7.
22. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
23. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: Data from the heart and soul study. Circulation 2003; 108: 2987-92.
24. Goldmann BU, Lagenbrink L, Matschuck G, Heeschen C, Kolbe-Busch S, Niederau C, Katz N, Wenserit C, Lestin HG, Brinken K, Kuhrt E, Tebbe U, Spanuth E, Hamm CW. Quantitative bedside testing of troponin T: Is it equal to laboratory testing? Clin Lab 2004; 50: 1-10.
25. Muller-Bardroff M, Sylven C, Rasmanis G, Jorgensen B, Collinson PO, Waldenhofer U, Hirschl MM, Laggner AN, Gerhardt W, Hafner G, Labaere I, Leinberger R, Zerback R, Katus HA. Evaluation of a point-of- care system for quantitative determination of troponin and myoglobin. Clin Chem Lab Med 2000; 38: 567-74.
26. Huysmans K, Lins RL, Daelemans R, Zachee P, De Broe ME. Hypertension and accelerated atherosclerosis in end-stage renal disease. J Nephrol 1998; 11: 185-95.
27. Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999; 14: 828-33.
28. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrisey R, Garcia A, Chiu A, De Maria A. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-74.
29. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, Wanner E, Maisel AS. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
30. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
31. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, Tahara A, Toda I, Takeuchi K, Kurihara N. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.
32. Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C, Uchida J, Nakatani T. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002; 22: 437-44.
33. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: A review. Clin Chemistry 2004; 50: 33-50.
34. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease theraphy. Kidney Int 1995; 47: 186-92.
35. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-90.
36. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-6.
37. Nitta K, Kawashima A, Yumura W, Naruse M, Oba T, Kabaya T, Nihei H. Plasma concentrations of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol 1998; 18: 411-5.
38. Sayama H, Nakamura Y, Saito N, Kinoshita M, Suda M. Relationship between left ventricular geometry and natriuretic peptide levels in elderly subjects. Gerontology 2000; 46: 71-7.
39. Nishikimi T, Futoo Y, Tamano K, Takahashi M, Suzuki T, Minami J, Honda T, Uetake S, Asakawa H, Kobayashi N, Horinaka S, Ishimitsu T, Matsuoka H. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: Influence of coronary artery disease. Am J Kidney Dis 2001; 37: 1201-8.
40. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS; CREED Investigators. The cardiovascular risk extended evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-6.
41. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS; CREED Investigators. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-15.